QIAGEN Exceeds Q4 & FY25 Outlook, Guides for At Least 5% Sales Growth in 2026

summarizeSummary

QIAGEN N.V. reported strong Q4 and full-year 2025 financial results, exceeding its own outlooks for sales and adjusted EPS, and provided a positive 2026 outlook for at least 5% CER sales growth and increased adjusted diluted EPS.

check_boxKey Events

• Strong 2025 Performance

  QIAGEN exceeded its Q4 and full-year 2025 sales and adjusted EPS outlooks. Full-year net sales reached $2.09 billion (+5% CER), and adjusted diluted EPS was $2.40 CER, ahead of guidance.

• Positive 2026 Outlook

  The company forecasts at least 5% CER net sales growth and adjusted diluted EPS of at least $2.50 CER for the full year 2026, driven by its growth pillars.

• Strategic Acquisitions & Capital Allocation

  QIAGEN completed the Parse Biosciences acquisition in Q4 2025, returned over $1.1 billion to shareholders in 2025, and executed a $500 million synthetic share repurchase in January 2026.

• Product Pipeline Advancement

  The company provided updates on new product launches and developments in automation, diagnostics (QIAstat-Dx, QIAcuity), and digital insights, including AI-enabled tools and new assay solutions.

auto_awesomeAnalysis

QIAGEN N.V. reported strong Q4 and full-year 2025 financial results, exceeding its own outlooks for sales and adjusted EPS, and provided a positive 2026 outlook for at least 5% CER sales growth and increased adjusted diluted EPS. The company demonstrated disciplined execution in 2025, driven by its growth pillars, and successfully integrated recent acquisitions like Parse Biosciences. While Q1 2026 adjusted EPS guidance is slightly below the prior year due to acquisition and tariff impacts, the full-year 2026 outlook remains robust, indicating continued operational strength and strategic expansion. Investors should note the company's active capital allocation, including significant shareholder returns and investments in its product pipeline.